J&J baby powder sample fails quality test: FDA latest lab report

The Bombay High Court, however, refused to give immediate relief on the matter and posted the matter for further hearing on December 6, 2022

339
Baby powder medicine
Picture: Pixabay

Last Updated on December 8, 2022 by The Health Master

Johnson & Johnson’s (J&J) baby powder sample has again failed the quality test as per the recent government analyst test report of the Maharashtra Food and Drug Administration (FDA) Laboratory in Mumbai.

According to the Maharashtra FDA report:

  • The sample tested did not meet the IS 5339:2004 specification for the test pH, which was above the prescribed limit of pH – 8.52.
  • pH is a figure that represents potential hydrogen and is the measure of acidity or alkalinity in any water-soluble substance.
  • pH values are represented on a logarithmic scale with numbers 1 to 14 with 7 being a neutral point.

November 16, 2022:

The Bombay High Court bench of Justices SV Gangapurwala and SG Chapalgaonkar had, on November 16, 2022, directed the Maharashtra FDA to send fresh samples of J&J baby powder from its Mulund facility in Mumbai for testing.

September 20, 2022:

The Central Drug Laboratory (CDL), Kolkata, test report had also found the powder containing higher pH levels than prescribed, on the basis of which the Maharashtra FDA had, on September 20, 2022, issued orders to immediately stop the manufacturing and sale of the company’s baby powder.

Following this, J&J filed a petition at the Bombay High Court (HC) challenging two orders of the state government, the first, dated September 15, with reference to canceling the license, and the second, dated September 20 with reference to stop and manufacturing baby powder.

December 6, 2022:

The Bombay High Court bench of Justices SV Gangapurwala and SG Chapalgaonkar, however, refused to give immediate relief on the matter and posted the matter for further hearing on December 6, 2022, to hear the Additional Government Pleader representing the Maharashtra government.

Voicing his concern in the larger public interest, Abhay Pandey, president of, the All Food and Drug Licence Holder Foundation (AFDLHF), has written to the Maharashtra FDA to add or club the pending cases related to baby powder with reference to writ petition number 984 of 2014 of Bombay HC filed by J&J with writ petition number 32004 of 2022 of Bombay HC to offer clarity in the case.

High Court asks Govt to re-examine Johnson & Johnson baby powder samples

After raids in Pune, FDA cancels production license of Johnson and Johnson’s baby powder unit

Johnson & Johnson to end global sales of talc-based baby powder

NPPA releases 3rd list with draft ceiling prices for 43 formulations

Drug recall: Sodium Bicarbonate Injection recalled due to this reason

USFDA-Gujarat FDCA to meet to discuss GMP compliance, capacity building

CDSCO panel gives nod for Esomeprazole Dual Release Gastro resistant tablets

Drug recall: Dr. Reddy’s, Sun Pharma recall these drugs due to this reason

USFDA gives nod for Diclofenac Sodium topical solution

IPC releases amendment list for IP 2022, details here

NPPA releases 2nd list with draft ceiling prices for 43 formulations

USFDA gives approval for Venlafaxine ER tablets

Latest Notifications regarding Pharmaceuticals

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news